Dare Bioscience, Inc. (DARE) financial statements (2021 and earlier)

Company profile

Business Address 3655 NOBEL DRIVE
SAN DIEGO, CA 92122
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments55783576
Cash and cash equivalents55783576
Receivables0100  
Prepaid expense2100  
Other current assets   0  
Other undisclosed current assets    21
Total current assets:76783777
Noncurrent Assets
Property, plant and equipment000 11
Intangible assets, net (including goodwill)   5  
Goodwill   5  
Other noncurrent assets111100
Total noncurrent assets:111611
TOTAL ASSETS:878143878
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:321169
Accounts payable   012
Accrued liabilities   056
Employee-related liabilities1100  
Other undisclosed accounts payable and accrued liabilities210   
Debt00  88
Business combination, contingent consideration, liability1     
Deferred revenue and credits 3 
Other undisclosed current liabilities330   
Total current liabilities:86111716
Noncurrent Liabilities
Long-term debt and lease obligation    413
Long-term debt, excluding current maturities    413
Liabilities, other than long-term debt110030
Deferred revenue and credits02 
Deferred revenue1 
Deferred rent credit  0
Other liabilities00  10
Business combination, contingent consideration, liability 1    
Total noncurrent liabilities:1100813
Total liabilities:97112529
Stockholders' equity
Stockholders' equity attributable to parent(1)07131349
Common stock000000
Additional paid in capital70453626214210
Accumulated other comprehensive loss(0)(0)(0)(0)  
Accumulated deficit(71)(44)(29)(12)(201)(161)
Total stockholders' equity:(1)07131349
TOTAL LIABILITIES AND EQUITY:878143878

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Gross profit:    1 
Operating expenses(27)(14)(17)(11)(38)(37)
Operating loss:(27)(14)(17)(11)(37)(37)
Nonoperating income (expense)000 (2)(2)
Other nonoperating income000   
Interest and debt expense   (0)(2)(2)
Other undisclosed loss from continuing operations before equity method investments, income taxes(0)(0)(0)(0)  
Loss from continuing operations before income taxes:(27)(14)(17)(12)(42)(42)
Income tax expense  (0)   
Net loss:(27)(14)(17)(12)(42)(42)
Other undisclosed net income attributable to parent000022
Net loss attributable to parent:(27)(14)(17)(12)(39)(40)
Preferred stock dividends and other adjustments(0)(1)    
Net loss available to common stockholders, diluted:(27)(15)(17)(12)(39)(40)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(27)(14)(17)(12)(42)(42)
Comprehensive loss:(27)(14)(17)(12)(42)(42)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(1)(0)(0)  
Comprehensive loss, net of tax, attributable to parent:(27)(15)(17)(12)(42)(42)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: